Literature DB >> 8913476

Effect of fluconazole on viability of Candida albicans over extended periods of time.

P G Sohnle1, B L Hahn, M D Erdmann.   

Abstract

The treatment of chronic mycoses may expose the infecting organisms to antimicrobial agents for extended periods of time. It is possible that an azole antifungal drug such as fluconazole, with primarily fungistatic activity in standard in vitro susceptibility tests, might be able to damage the fungal cells and reduce their viability over prolonged incubations under nonproliferating conditions. To test this possibility, Candida albicans yeast cells were exposed to various concentrations of fluconazole in RPMI 1640 tissue culture medium for 4 h at 37 degrees C, washed free of the drug, and then incubated at 37 degrees C for a 28-day period; enumeration of the remaining CFU at various times during this period revealed no increased loss of viability for the fluconazole-exposed organisms. However, when fluconazole was added to the organisms maintained in distilled water (with or without pretreatment with the drug), a marked reduction of viability was found. At 14 days of incubation with two strains of C. albicans, negative cultures were found for 7 of 10 and 10 of 11 samples, respectively, containing 1.0 microgram of fluconazole per ml versus 0 of 10 and 1 of 11 control samples (P of < 0.01 and 0.001, respectively). The effect of fluconazole on fungal viability under these conditions became noticeable at approximately 7 days and was greater when the samples were incubated at 37 degrees C rather than 25 degrees C. These findings suggest that fluconazole may have fungicidal effects on fungal cells during prolonged exposures under conditions in which the organisms are prevented from proliferating by lack of nutrients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913476      PMCID: PMC163587     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies.

Authors:  J N Galgiani
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

2.  Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans.

Authors:  H van den Bossche; G Willemsens; W Cools; W F Lauwers; L Le Jeune
Journal:  Chem Biol Interact       Date:  1978-04       Impact factor: 5.192

3.  Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

Review 4.  Antifungal susceptibility testing of yeasts: a brief overview.

Authors:  D J Sheehan; A Espinel-Ingroff; L S Moore; C D Webb
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

5.  Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles.

Authors:  C E Hughes; W H Beggs
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

6.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole.

Authors:  C Brass; J N Galgiani; S C Campbell; D A Stevens
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

8.  Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients.

Authors:  J R Graybill; D Lundberg; W Donovan; H B Levine; M D Rodriguez; D J Drutz
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

9.  Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole.

Authors:  S De Nollin; H Van Belle; F Goossens; F Thone; M Borgers
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

10.  Selective inhibition of 14 alpha-desmethyl sterol synthesis in Candida albicans by terconazole, a new triazole antimycotic.

Authors:  D M Isaacson; E L Tolman; A J Tobia; M E Rosenthale; J L McGuire; H Vanden Bossche; P A Janssen
Journal:  J Antimicrob Chemother       Date:  1988-03       Impact factor: 5.790

View more
  6 in total

Review 1.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

2.  Simple and reliable detection of slime production of Candida spp. directly from blood culture bottles: comparison of visual tube method and transmission electron microscopy.

Authors:  Nilgun Cerikcioglu; Ufuk Over Hasdemir; Tangul San; Emsal Salik; Guner Soyletir
Journal:  Mycopathologia       Date:  2004-10       Impact factor: 2.574

3.  Analysis of volatile fingerprints for monitoring anti-fungal efficacy against the primary and opportunistic pathogen Aspergillus fumigatus.

Authors:  Neus Planas Pont; Catherine A Kendall; Naresh Magan
Journal:  Mycopathologia       Date:  2011-10-14       Impact factor: 2.574

4.  Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.

Authors:  Peter G Sohnle; Beth L Hahn
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium.

Authors:  Mahomed-Yunus S Moosa; Jack D Sobel; Hussain Elhalis; Wenjin Du; Robert A Akins
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

6.  Candida albicans Infections: a novel porcine wound model to evaluate treatment efficacy.

Authors:  Joel Gil; Michael Solis; Alexander Higa; Stephen C Davis
Journal:  BMC Microbiol       Date:  2022-02-04       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.